Loading...

Brilliant Violet 421™ anti-mouse F4/80 Antibody

Pricing & Availability
Clone
BM8 (See other available formats)
Regulatory Status
RUO
Other Names
EMR1, Ly71
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_BM8_BV421_F4slash80_Antibody_1_FC_060616
Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 1_BM8_BV421_F4slash80_Antibody_1_FC_060616
    Thioglycolate-elicited Balb/c mouse peritoneal macrophages were stained with F4/80 (clone BM8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • 2_BM8_BV421_F4slash80_Antibody_2_IHCF_060616
    C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS plus 5% rat/mouse serum for 30 minutes at room temperature. Then the section was stained with 2 µg/ml of anti-mouse F4/80 (clone BM8) Brilliant Violet 421™ (Blue) and anti-mouse CD8a (clone 53-6.7) Alexa Fluor® 647 (red) overnight at 4°C. The image was captured with a 10X objective.
  • 34_Mouse_Spleen_F480_MHCII
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: MHCII (blue) in Cycle 2 and F4/80 (magenta) in Cycle 2. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 59_Mouse_Lymph_Node_F480_CD68_NK1.1
    Mice were injected subcutaneously with sheep red blood cells in a volume of 25 µl per site on days 0 and 4 and harvested on day 11. Confocal image of C57BL/6 mouse lymph node acquired using the IBEX method of highly multiplexed antibody-based imaging: F4/80 (cyan) in Cycle 3, CD68 (blue) in Cycle 6, and NK1.1 (magenta) in Cycle 9. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Brilliant Violet 421™ spectral data See high resolution IHC data...
Cat # Size Price Save
123131 125 µL ¥44,880
123137 50 µg ¥55,660
123132 500 µL ¥87,120
Description

F4/80, also known as EMR1 or Ly71, is a 160 kD glycoprotein of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80 has been widely used as a murine macrophage marker. It is expressed on a majority of tissue macrophages, including macrophages in the lung, gut, peritoneal cavity, thymus, and red pulp of the spleen, Kupffer cells, Langerhans cells, microglia, and certain dendritic cells. It is not expressed on macrophages located in the T cell areas of the spleen, lymph node, or Peyer's patch. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for the induction of CD8+ T cells-mediated peripheral tolerance.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Murine macrophages
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemical staining on frozen tissue sections, the suggested use of this reagent is 2.0 µg/ml. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections1,2 and formalin-fixed paraffin-embedded sections6,7, Western blotting, and spatial biology (IBEX)12,13.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Schaller E, et al. 2002. Mol. Cell. Biol. 22:8035. (IHC)
  2. Stevceva L, et al. 2001. BMC Clin Pathol. 1:3. (IHC)
  3. Kobayashi M, et al.2008. J. Leukoc. Biol. 83:1354. PubMed
  4. Poeckel D, et al. 2009. J. Biol Chem. 284:21077. PubMed
  5. Glass AM, et al. 2013. J. Immunol. 190:4830. PubMed
  6. Koehm S, et al. 2007. J. Allergy Clin. Immunol. 120:570. (IHC)
  7. Rankin AL, et al. 2010. J. Immunol. 184:1526. (IHC)
  8. Sasi SP, et al. 2014. J Biol Chem. 289:14178. PubMed
  9. Thakus VS, et al. 2014. Toxicol Lett. 230:322. PubMed
  10. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
  11. Hirakawa H, et al. 2015. PLoS One. 10:119360. PubMed
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  2. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  3. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  4. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  5. Miranda K, et al. 2022. iScience. 25:104994. PubMed
  6. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  7. Wang L, et al. 2022. Cell Metab. 34:75. PubMed
  8. Zhang Y, et al. 2022. J Cereb Blood Flow Metab. 42:952. PubMed
  9. Kang H, et al. 2022. Adv Mater. 34:e2106500. PubMed
  10. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  11. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  12. Zhang Z, et al. 2022. Mol Nutr Food Res. 66:e2200300. PubMed
  13. Lu Z, et al. 2022. Cell Rep. 41:111482. PubMed
  14. Siret C, et al. 2022. Nat Commun. 13:7366. PubMed
  15. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  16. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  17. Taniguchi S, et al. 2023. Nat Commun. 14:143. PubMed
  18. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  19. Yang L, et al. 2023. Sci Rep. 13:1827. PubMed
  20. Wu Q, et al. 2023. Cell Rep. 42:112057. PubMed
  21. Zhao X, et al. 2022. Cell Mol Immunol. 19:540. PubMed
  22. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  23. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  24. Wu Q, et al. 2023. Front Immunol. 13:1081719. PubMed
  25. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  26. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  27. Bautista CA, et al. 2023. Front Physiol. 14:1122348. PubMed
  28. Guo Z, et al. 2023. Int J Mol Sci. 24:. PubMed
  29. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  30. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  31. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  32. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  33. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  34. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  35. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  36. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  37. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  38. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  39. Feng J, et al. 2021. iScience. 24:103004. PubMed
  40. Li J, et al. 2021. Front Immunol. 12:649285. PubMed
  41. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  42. Iturri L, et al. 2021. Immunity. . PubMed
  43. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  44. Sakai M, et al. 2020. Immunity. 51(4):655-670. PubMed
  45. Nakamoto N, et al. 2019. Nat Microbiol. 4:492. PubMed
  46. Brunner JS, et al. 2020. Nat Commun. 0.757638889. PubMed
  47. Sun K, et al. 2016. J Exp Med. 213: 1851 - 1864. PubMed
  48. Laumonnier Y, et al. 2020. Curr Protoc Immunol. 130:e100. PubMed
  49. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  50. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  51. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
  52. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  53. Croasdell A, et al. 2016. J Immunol. 196: 2742 - 2752. PubMed
  54. Karsten C, et al. 2015. J Immunol. 194:1841. PubMed
  55. Lyons J, et al. 2018. Sci Signal. 11. PubMed
  56. Sokol CL et al. 2018. Immunity. 49(3):449-463 . PubMed
  57. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  58. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  59. Glass A, et al. 2013. J Immunol. 190:4830. PubMed
  60. Müller P, et al. 2015. Sci Transl Med. 7: 315ra188. PubMed
  61. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  62. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  63. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  64. Du W, et al. 2021. Mol Cancer Res. 19:1412. PubMed
  65. Opzoomer JW, et al. 2021. Sci Adv. 7:eabg9518. PubMed
  66. Paterson N, et al. 2022. Elife. 11:. PubMed
  67. Eggold JT, et al. 2022. Mol Cancer Ther. 21:371. PubMed
  68. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  69. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  70. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  71. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
  72. Li J, et al. 2020. Elife. 9:00. PubMed
  73. Fennell LM, et al. 2020. EMBO J. 39:e103303. PubMed
  74. Chi A, et al. 2022. Front Endocrinol (Lausanne). 13:871548. PubMed
  75. Friedman DJ, et al. 2021. Cancer Immunol Res. 9:952. PubMed
  76. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  77. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  78. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  79. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  80. Cao DY, et al. 2020. J Biol Chem. 295:1369. PubMed
  81. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
  82. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  83. He J, et al. 2019. J Clin Invest. 130. PubMed
  84. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  85. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  86. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  87. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Troutman TD, et al. 2021. STAR Protocols. 2(1):100363. PubMed
  89. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  90. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  91. Khare P, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.09.002. PubMed
  92. Lim J et al. 2019. Elife. 8 pii: e44452. PubMed
  93. McDonald LT, et al. 2018. Am J Physiol Heart Circ Physiol. 315:H92. PubMed
  94. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  95. Chuang CH, et al. 2020. Cancer Research. 81:567. PubMed
  96. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  97. Babagana M, et al. 2021. Aging (Albany NY). 13:19207. PubMed
  98. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  99. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  100. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  101. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  102. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  103. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  104. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  105. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  106. Ledo JH, et al. 2020. PLoS One. e0237773:15. PubMed
  107. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  108. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  109. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  110. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  111. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  112. Heinen A, et al. 2019. Mol Ther. 27:46:00. PubMed
  113. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  114. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  115. Liao X, et al. 2022. JCI Insight. 7:. PubMed
  116. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  117. Fan HH, et al. 2021. Methods Mol Biol. 2276:203. PubMed
  118. Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed
  119. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  120. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  121. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  122. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  123. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  124. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  125. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  126. Shan Z, et al. 2021. eLife. 10:00. PubMed
  127. Ying L, et al. 2021. Front Cell Dev Biol. 9:672032. PubMed
  128. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  129. Schuster EM, et al. 2022. Nat Metab. 4:856. PubMed
  130. Ledo JH, et al. 2020. Mol Psychiatry. . PubMed
  131. Cai W, et al. 2019. J Neuroinflammation. 0.788194444. PubMed
  132. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  133. Pessoa Rodrigues C, et al. 2020. Sci Adv. 6:eaaz4815. PubMed
  134. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
  135. Yao W, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.07.014. PubMed
RRID
AB_10901171 (BioLegend Cat. No. 123131)
AB_10901171 (BioLegend Cat. No. 123137)
AB_10901171 (BioLegend Cat. No. 123132)

Antigen Details

Structure
EGF-TM7 family member, 160 kD glycoprotein
Distribution

Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kupffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells

Function
Induction of immunological tolerance
Cell Type
Dendritic cells, Langerhans cells, Macrophages, Tregs
Biology Area
Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Antigen References

1. Austy JM and Gordon S. 1981. Eur. J. Immunol. 11:805.
2. Hume DA, et al. 1983. J. Exp. Med. 158:1522.
3. Ruedl C, et al. 1996. Eur. J. Immunol. 26:1801.
4. McKnight AJ, et al. 1996. J. Biol. Chem. 271:486.
5. Lin HH, et al. 2005. J. Exp. Med. 201:1615.

Gene ID
13733 View all products for this Gene ID
UniProt
View information about F4/80 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All F4/80 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 605™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 BM8 FC,IHC,WB
Biotin anti-mouse F4/80 BM8 FC,IHC
FITC anti-mouse F4/80 BM8 FC
PE anti-mouse F4/80 BM8 FC
PE/Cyanine5 anti-mouse F4/80 BM8 FC
PE/Cyanine7 anti-mouse F4/80 BM8 FC
APC anti-mouse F4/80 BM8 FC
APC/Cyanine7 anti-mouse F4/80 BM8 FC
Alexa Fluor® 488 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse F4/80 BM8 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse F4/80 BM8 FC
PerCP anti-mouse F4/80 BM8 FC
PerCP/Cyanine5.5 anti-mouse F4/80 BM8 FC
Alexa Fluor® 700 anti-mouse F4/80 BM8 FC
Brilliant Violet 421™ anti-mouse F4/80 BM8 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse F4/80 BM8 FC
Alexa Fluor® 594 anti-mouse F4/80 BM8 IHC-F
Brilliant Violet 785™ anti-mouse F4/80 BM8 FC
Purified anti-mouse F4/80 (Maxpar® Ready) BM8 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse F4/80 BM8 FC
Brilliant Violet 650™ anti-mouse F4/80 BM8 FC
Brilliant Violet 711™ anti-mouse F4/80 BM8 FC
APC/Fire™ 750 anti-mouse F4/80 BM8 FC
TotalSeq™-A0114 anti-mouse F4/80 BM8 PG
TotalSeq™-B0114 anti-mouse F4/80 BM8 PG
TotalSeq™-C0114 anti-mouse F4/80 BM8 PG
Spark YG™ 570 anti-mouse F4/80 BM8 IHC-F
KIRAVIA Blue 520™ anti-mouse F4/80 BM8 FC
Ultra-LEAF™ Purified anti-mouse F4/80 BM8 FC,IHC,WB
APC/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark NIR™ 685 anti-mouse F4/80 BM8 FC
Spark Blue™ 550 anti-mouse F4/80 BM8 FC
Brilliant Violet 570™ anti-mouse F4/80 BM8 FC
Brilliant Violet 750™ anti-mouse F4/80 BM8 FC
PE/Fire™ 810 anti-mouse F4/80 BM8 FC
Spark Red™ 718 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
Spark Blue™ 574 anti-mouse F4/80 (Flexi-Fluor™) BM8 FC
Go To Top Version: 4    Revision Date: 04/20/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account